FDA
-
-
-
-
-
-
-
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipelin
-
-
-
-
-
-
-
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
-
-
-
-
-
-
-
Entera Bio outlines Q1 2026 milestones for osteoporosis drug
-
-
-
-
-
-
-
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
-
-
-
-
-
-
-
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
-
-
-
-
-
-
-
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
-
-
-
-
-
-
-
Entera Bio Ltd. (ENTX) Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

